Can Naloxone Be Used to Treat Synthetic Cannabinoid Overdose?

Affiliations

¹ Division of Substance Abuse, New York Psychiatric Institute, College of Physicians and Surgeons of Columbia University, New York; Department of Psychiatry, College of Physicians and Surgeons of Columbia University, New York; Bureau of Alcohol and Drug Use Prevention, Care and Treatment, New York City Department of Health and Mental Hygiene, Long Island City, New York. Electronic address: jonesje@NYSPI.Columbia.edu.
² Bureau of Alcohol and Drug Use Prevention, Care and Treatment, New York City Department of Health and Mental Hygiene, Long Island City, New York.
³ Public Health/Preventive Medicine Residency Program, New York City Department of Health and Mental Hygiene, Long Island City, New York; Bureau of Alcohol and Drug Use Prevention, Care and Treatment, New York City Department of Health and Mental Hygiene, Long Island City, New York.
⁴ Division of Substance Abuse, New York Psychiatric Institute, College of Physicians and Surgeons of Columbia University, New York; Department of Psychiatry, College of Physicians and Surgeons of Columbia University, New York.

Jermaine D Jones et al. Biol Psychiatry. 2017.

. 2017 Apr 1;81(7):e51-e52.

doi: 10.1016/j.biopsych.2016.08.013. Epub 2016 Aug 18.

¹ Division of Substance Abuse, New York Psychiatric Institute, College of Physicians and Surgeons of Columbia University, New York; Department of Psychiatry, College of Physicians and Surgeons of Columbia University, New York; Bureau of Alcohol and Drug Use Prevention, Care and Treatment, New York City Department of Health and Mental Hygiene, Long Island City, New York. Electronic address: jonesje@NYSPI.Columbia.edu.
² Bureau of Alcohol and Drug Use Prevention, Care and Treatment, New York City Department of Health and Mental Hygiene, Long Island City, New York.
³ Public Health/Preventive Medicine Residency Program, New York City Department of Health and Mental Hygiene, Long Island City, New York; Bureau of Alcohol and Drug Use Prevention, Care and Treatment, New York City Department of Health and Mental Hygiene, Long Island City, New York.
⁴ Division of Substance Abuse, New York Psychiatric Institute, College of Physicians and Surgeons of Columbia University, New York; Department of Psychiatry, College of Physicians and Surgeons of Columbia University, New York.

No abstract available

References

1. Castaneto MS, Gorelick DA, Desrosiers NA, Hartman RL, Pirard S, Huestis MA. Synthetic cannabinoids: Epidemiology, pharmaco-dynamics, and clinical implications. Drug Alcohol Depend. 2014;144:12–41. - PMC - PubMed
1. Justinova Z, Tanda G, Munzar P, Goldberg SR. The opioid antagonist naltrexone reduces the reinforcing effects of Delta 9 tetrahydrocannabinol (THC) in squirrel monkeys. Psychopharmacology (Berl) 2004;173:186–194. - PubMed
1. Rosenbaum CD, Carreiro SP, Babu KM. Here today, gone tomorrow…and back again? A review of herbal marijuana alternatives (K2, Spice), synthetic cathinones (bath salts), kratom, Salvia divinorum, methoxetamine, and piperazines. J Med Toxicol. 2012;8:15–32. - PMC - PubMed
1. Substance Abuse and Mental Health Services Administration. SAMHSA Opioid Overdose Prevention Toolkit. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2016. HHS Publication No. SMA16-4742.
1. Robledo P, Berrendero F, Ozaita A, Maldonado R. Advances in the field of cannabinoid–opioid cross-talk. Addict Biol. 2008;13:213–224. - PubMed